David Zanoni Blog | Northrop Grumman: Immunity From The Coronavirus With A Lower Valuation | Talkmarkets
Financial Blogger/Operations Supervisor
Contributor's Links: Momentum at a Reasonble Price

David Zanoni is a contributor to Kirk Spano's Margin of Safety Investing service. David is ranked in the top 1% of blogging analysts on Tipranks.com for performance and accuracy. He focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over ... more

Northrop Grumman: Immunity From The Coronavirus With A Lower Valuation

Date: Monday, March 23, 2020 10:08 PM EDT

Most of the defense-related companies have a positive future outlook. This is a result of the steady expected annual growth of about 3% through 2023 for U.S. defense spending. The company that I'm focusing on in this article is the global security firm Northrop Grumman (NOC).

Northrop looks like a solid investment due to its backlog growth of 21% in 2019 over the prior year. Bookings increased at a strong pace at 66% over the same time period. Northrop tends to be awarded lucrative contracts on an ongoing basis, which drives this growth, leading to revenue and earnings increases.

CLICK LINK TO READ ENTIRE ARTICLE: https://seekingalpha.com/article/4333727-northrop-grumman-immunity-from-coronavirus-lower-valuation

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.


Leave a comment to automatically be entered into our contest to win a free Echo Show.